Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5508)
All Articles published online
|
Publishing Process of This Article
|
Jul 16, 2022 (publication date) through Apr 24, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Cases
ISSN
2307-8960
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Cigrovski Berkovic M, Rezic T, Bilic-Curcic I, Mrzljak A. Semaglutide might be a key for breaking the vicious cycle of metabolically associated fatty liver disease spectrum? World J Clin Cases 2022; 10(20): 6759-6768 [PMID: 36051145 DOI: 10.12998/wjcc.v10.i20.6759] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v10/i20/6759.htm |
| Number | Citing Articles |
| 1 |
Sandip Mukherjee, Molee Chakraborty, Jake Haubner, Glen Ernst, Michael DePasquale, Danielle Carpenter, James C. Barrow, Anutosh Chakraborty. The IP6K Inhibitor LI-2242 Ameliorates Diet-Induced Obesity, Hyperglycemia, and Hepatic Steatosis in Mice by Improving Cell Metabolism and Insulin Signaling. Biomolecules 2023; 13(5): 868 doi: 10.3390/biom13050868
|
| 2 |
Evgenia Koureta, Evangelos Cholongitas. Evolving role of semaglutide in NAFLD: in combination, weekly and oral administration. Frontiers in Pharmacology 2024; 15 doi: 10.3389/fphar.2024.1343587
|
| 3 |
Zeyu Xie, Sensen Yang, Weishang Deng, Jinjian Li, Jisheng Chen. Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review. Clinical Epidemiology 2022; : 1463 doi: 10.2147/CLEP.S391819
|